CD19 CAR-T / Vyriad - LARVOL DELTA

In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector (ASH 2023) - "In contrast, CAR-T cells were not detected at any time point in humanized NSG mice injected with G-WT LV, regardless of whether the virus was administered IV or IP. In summary, these data highlight the potential applicability of fully retargeted, serum stable LVs for in vivo gene delivery or genome editing, offering promising prospects for future human gene therapy applications."

CAR T-Cell Therapy • IO biomarker • Preclinical • Viral vector • Gene Therapies • Infectious Disease • IL2RA • PTPRC

Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification. (PubMed, Mol Ther Oncol) - "Here, we used an oncolytic foamy virus (oFV) to display a model CAR target antigen (CD19) on tumors in combination with anti-CD19 CAR T cells...Therefore, oFV represents a slow smoldering type of oncolytic virus, whose chronic spread through tumors generates anti-tumor therapy, which is abolished by CAR T therapy. These results suggest that further development of this oncolytic platform, with additional immunotherapeutic arming, may allow for an effective combination of chronic oncolysis."

IO biomarker • Journal • Oncolytic virus • Oncology • Solid Tumor • CD19

In Vivo Generation of αCD19-CAR T Cells Using a Novel LV-based Platform Successfully Clears Advanced NALM-6 Tumor without Noticeable Toxicity (ASGCT 2024) - "Our study also demonstrates the safety and tolerability of our new platform in mice during treatment. These promising results support the need for further investigations into the efficiency and safety of in vivo treatments utilizing this groundbreaking platform."

CAR T-Cell Therapy • IO biomarker • Metastases • Preclinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • CD69 • IFNG • IL10 • IL2 • IL2RA • IL4 • IL6 • TNFA

Vyriad Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting (PRNewswire) - "Vyriad, Inc...today announced that its abstract, In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector, has been selected for an oral presentation at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, California. Vyriad's presentation will discuss progress in developing its highly targeted, efficient, serum-stable and durable lentiviral vector technology to deliver genetic payloads directly and specifically to CD3+ T cells."

Preclinical